Neuronetics (NASDAQ:STIM) issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.05), MarketWatch Earnings reports. The company had revenue of $12.73 million for the quarter, compared to the consensus estimate of $12.72 million. Neuronetics had a negative return on equity of 1,385.60% and a negative net margin of 47.21%. Neuronetics updated its Q2 2019 guidance to EPS and its FY 2019 guidance to EPS.
Shares of STIM opened at $11.33 on Friday. Neuronetics has a one year low of $11.19 and a one year high of $39.39. The stock has a market capitalization of $222.99 million and a PE ratio of -4.21. The company has a quick ratio of 8.74, a current ratio of 8.94 and a debt-to-equity ratio of 0.52.
In other news, insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Thatcher sold 15,000 shares of Neuronetics stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $16.82, for a total transaction of $252,300.00. The disclosure for this sale can be found here. In the last three months, insiders sold 76,571 shares of company stock valued at $1,209,929. Insiders own 12.00% of the company’s stock.
A number of research analysts recently weighed in on STIM shares. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Neuronetics in a research report on Wednesday, March 6th. Zacks Investment Research raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, Piper Jaffray Companies decreased their target price on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating for the company in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $31.60.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Article: Hedge Funds – Risk or Reward?
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.